As the stock market crash continues, I’d buy these 2 FTSE 100 stocks in an ISA right now

These two FTSE 100 (INDEXFTSE:UKX) shares could offer long-term growth prospects, in Peter Stephens’ opinion.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

The FTSE 100’s 32% crash since the start of the year could continue in the coming weeks. The situation regarding coronavirus is impossible to accurately predict. That may lead to investors demanding even wider margins of safety from large-cap shares.

However, valuations now suggest there could be opportunities for long-term investors. Many FTSE 100 stocks offer wide margins of safety and the potential for improving returns in the coming years.

As such, now could be the right time to buy these two stocks as part of a diverse ISA portfolio, and hold them for the long run.

AstraZeneca

AstraZeneca’s (LSE: AZN) defensive characteristics have been evident in recent weeks. Its shares are down by 10% in 2020, which is less than a third of the FTSE 100’s decline.

The company is less reliant on the world economy’s performance for its sales. But disruption to global supply chains and weak economic performance may have a negative impact on the pharmaceutical and biopharmaceutical giant’s performance in the near term.

However, AstraZeneca’s recent updates have shown it’s making headway in delivering improving financial performance. For example, its new medicines recorded sales growth of 62% last year. Since they now make up 42% of its total product sales, they’re likely to have a significant impact on its future financial performance.

The stock’s recent decline means that it appears to offer relatively good value for money. It’s forecast to post a rise in its bottom line of 27% next year. Trading on a price-to-earnings (P/E) ratio of 21. And having a defensive business model means that now could be the right time to buy a slice of AstraZeneca and hold those shares for the long run.

RBS

While AstraZeneca offers defensive characteristics, other FTSE 100 stocks, such as RBS (LSE: RBS), have fallen by a much greater amount than the index in recent weeks. The bank’s share price is down by 52% since the start of the year, as investors have reacted to a challenging outlook for the UK economy.

Furthermore, the banking sector may find the task of generating improving returns more difficult in a low interest rate environment. With interest rates at historic lows and monetary policy likely to remain accommodative over the medium term, the financial prospects for the banking industry could prove to be challenging.

However, RBS now trades on a P/E ratio of around 6. This suggests investors have priced in the potential difficulties it may face, and that it now offers a wide margin of safety.

Certainly, it may experience further declines in the short run. But, with its recent results showing an improving operational performance from the bank, now could be a buying opportunity. That’s the case for long-term investors who can accept short-term volatility for high-potential rewards in the coming years.

Peter Stephens owns shares of AstraZeneca and Royal Bank of Scotland Group. The Motley Fool UK has recommended AstraZeneca. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Will the S&P 500 crash in 2026?

The S&P 500 delivered impressive gains in 2025, but valuations are now running high. Are US stocks stretched to breaking…

Read more »

Teenage boy is walking back from the shop with his grandparent. He is carrying the shopping bag and they are linking arms.
Investing Articles

How much do you need in a SIPP to generate a brilliant second income of £2,000 a month?

Harvey Jones crunches the numbers to show how investors can generate a high and rising passive income from a portfolio…

Read more »

Investing Articles

Will Lloyds shares rise 76% again in 2026?

What needs to go right for Lloyds shares to post another 76% rise? Our Foolish author dives into what might…

Read more »

Investing Articles

How much passive income will I get from investing £10,000 in an ISA for 10 years?

Harvey Jones shows how he plans to boost the amount of passive income he gets when he retires, from FTSE…

Read more »

Investing Articles

Down 34% in 2025 — but could this be one of the UK’s top growth stocks for 2026?

With clarity over research funding on the horizon, could Judges Scientific be one of the UK’s best growth stocks to…

Read more »

piggy bank, searching with binoculars
Investing Articles

Can the rampant Barclays share price beat Lloyds in 2026?

Harvey Jones says the Barclays share price was neck and neck with Lloyds over the last year, and checks out…

Read more »

Investing Articles

Here’s how Rolls-Royce shares could hit £25 in 2026

If Rolls-Royce shares continue their recent performance, then £25 might be on the cards for 2026. Let's take a look…

Read more »

Departure & Arrival sign, representing selling and buying in a portfolio
Investing Articles

Prediction: in 2026 the red-hot Rolls-Royce share price could turn £10,000 into…

Harvey Jones can't believe how rapidlly the Rolls-Royce share price has climbed. Now he looks at the FTSE 100 growth…

Read more »